Summary
PharmaResearch (214450:KQ) achieved record sales in 2Q24, with a 25% YoY revenue increase to KRW 83.3 billion. Strong domestic demand for Rejuran and 20% expected growth in exports are backed by Aicel's reliable data.
An Overview of PharmaResearch's Business Segments
PharmaResearch operates across several business segments, including pharmaceuticals, medical devices, cosmetics, and others. The company's diverse portfolio has contributed to its robust growth, particularly evident in the second quarter of 2024. During this period, PharmaResearch achieved record quarterly revenues of KRW 83.3 billion, reflecting a 25% year-on-year increase. The company's stock price has also seen significant appreciation, driven by strong domestic sales and an increasing share of exports.
Reviewing PharmaResearch's Overseas Revenue with Aicel Trade Data
A key highlight of PharmaResearch's 2Q24 performance is the substantial growth in its overseas revenue. According to Aicel's trade data, the company's exports were expected to grow by 20% on an FX-neutral basis. This growth is supported by increased shipments from Gangneung City, where PharmaResearch's manufacturing facilities and headquarters are located, to major markets such as China, Japan, and Singapore. A strong correlation of over 91% between PharmaResearch's overseas sales and Aicel's trade data from 1Q22 to 2Q24 underscores the accuracy and reliability of these projections.
Analyzing PharmaResearch's Domestic Revenue with Aicel Consumer Transaction Data
Domestically, PharmaResearch has continued to benefit from the growing demand for its flagship product, Rejuran. Aicel's consumer transaction data indicated that domestic sales maintained a strong upward trajectory in 2Q24, driven by the booming medical device market. The correlation between PharmaResearch's domestic sales and Aicel's consumer transaction data has been recorded at over 98% from 1Q22 to 2Q24, highlighting the consistent alignment between market trends and actual sales performance.
Aicel Data Analysis: A Tool for Business Insights
The use of Aicel's data analysis tools has proven invaluable in providing early insights into PharmaResearch's financial performance. By monitoring both domestic and international sales, Aicel's data offers a comprehensive view of the company's business segments, enabling a more accurate forecast of financial health before the release of official results. This capability is particularly beneficial for investors looking to gain an edge in their strategic decision-making processes.
Conclusion: Record Sales Driven by Strong Data Insights
PharmaResearch's 2Q24 performance showcases the company's strength in both domestic and international markets, with record sales driven by the success of its Rejuran product and expanding export operations. The alignment of PharmaResearch's sales with Aicel's data underscores the effectiveness of utilizing alternative data for early financial insights. All data in this analysis is sourced from Aicel Technologies, providing diverse investment insights and enabling continuous strategic evaluations.
This article is also posted on Linkedin
